Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.

导出 OA

翻译打印收藏纠错

第一作者： Yuwa,Ando

第一单位： Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.

作者： Yuwa,Ando ^[1] ; Tomokazu,Kawaoka ^[1] ; Masanari,Kosaka ^[1] ; Yuki,Shirane ^[1] ; Yusuke,Johira ^[1] ; Ryoichi,Miura ^[1] ; Serami,Murakami ^[1] ; Shigeki,Yano ^[1] ; Kei,Amioka ^[1] ; Kensuke,Naruto ^[1] ; Yumi,Kosaka ^[1] ; Shinsuke,Uchikawa ^[1] ; Kenichiro,Kodama ^[1] ; Hatsue,Fujino ^[1] ; Takashi,Nakahara ^[1] ; Atsushi,Ono ^[1] ; Eisuke,Murakami ^[1] ; Masami,Yamauchi ^[1] ; Wataru,Okamoto ^[2] ; Shoichi,Takahashi ^[2] ; Michio,Imamura ^[1] ; Kazuaki,Chayama ^[1] ; Hiroshi,Aikata ^[3]

作者单位： Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan. ^[1] Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima 734-8551, Japan. ^[2] Collaborative Research Laboratory of Medical Innovation, Hiroshima University, Hiroshima 734-8551, Japan. ^[3] Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima 734-8551, Japan. ^[4] RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan. ^[5]

关键词 atezolizumab bevacizumab hepatocellular carcinoma immune checkpoint inhibitor molecular targeted agents real-world practice tumor marker α-fetoprotein

DOI 10.3390/cancers13163958

PMID 34439111

发布时间 2024-04-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交